Bayer (BAYN) Wins FDA Priority Review for Lynkuet sNDA

FDA accepted Bayer’s sNDA and granted Priority Review for Lynkuet (elinzanetant) to treat moderate to severe vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.Material DetailsContext by AI AnalystThis is a late-stage regulatory step building on Lynkuet’s 2025 menopause VMS appr…